PD-L1 cut-off and assay compatibility

Vantrexa · Metastatic NSCLC

MI-2026-0075RoutineClosedWithin SLA

RARachel AdeyemiMSL, Oncology (UK & Ireland)

Received: 16 Jun 2026, 11:22 UTC
Channel: Web portal
Requestor type: Internal
Country / region / team: United States · North America · MI Americas
Category: Administration
Response type: Standard response
Owner: RARachel Adeyemi
Due: 21 Jun 2026, 11:22 UTC
Responded: 18 Jun 2026, 12:22 UTC
Quality review: Not required
Related insight: —
Related standard response: SR-VTX-001 · PD-L1 cut-off and assay compatibility (v3)

Workflow

12-stage inquiry workflow (PRD §16). Advancing records an audit event.

Current stageClosedDemo action — not persisted

Routine: 120 h target · Routine 120 h / Urgent 48 h / Critical 24 h

SLA hours

120

Elapsed

49 h

to response

Remaining

71 h

41%

16 Jun 2026, 11:22 UTC
Received via Web portal
Internal · United States
16 Jun 2026, 11:22 UTC
Triage and assignment
Urgency Routine · assigned to MI Americas
18 Jun 2026, 12:22 UTC
Response sent
Standard response · quality review not required
21 Jun 2026, 11:22 UTC
SLA due (120 h)

Demo — drafts are not persisted

AI suggestion available for non-safety inquiries

Draft response

Timestamp	Action	User	Field	Change	Reason	Source	Event
05 Sept 2026, 06:51 UTC	Update	James Whitfield	progress	— → Completed	—	UI	AUD-002011

Data lineage: MI inquiry platform (IRMS, INT-05) · received 16 Jun 2026 · hourly sync.